Hopp til hovedinnhold

Fampridin - Fampyra

Sist oppdatert: Sist revidert:
Sist revidert av:

  1. Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR; MSF204 Investigators. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010; 68: 494-502. PMID: 20976768 PubMed  
  2. Allart E, Benoit A, Blanchard-Dauphin A, Tiffreau V, Thevenon A, Zephir H, Outteryck O, Lacour A, Vermersch P. Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life. J Neurol. 2015 Aug;262(8):1936-45 . pmid:26041616 PubMed  
  3. Jensen HB, Ravnborg M, Dalgas U, Stenager E. 4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review. Ther Adv Neurol Disord. 2014 Mar;7(2):97-113 . pmid:24587826 PubMed  
  4. De Giglio L, De Luca F, Gurreri F, Ferrante I, Prosperini L, Borriello G, Quartuccio E, Gasperini C, Pozzilli C. Effect of dalfampridine on information processing speed impairment in multiple sclerosis. Neurology. 2019 Aug 20;93(8):e733-e746. PMID: 31331968 PubMed  
  5. Birnbaum G, Iverson J. Dalfampridine may activate latent trigeminal neuralgia in patients with multiple sclerosis.. Neurology. 2014 ; Oct 28;83(18): 1610-2. pmid:25261505 PubMed  
  • Hanne Marie Bøe Lunde, spesialist i nevrologi, PhD
  • Øyvind Fredvik Grytten Torkildsen, spesialist i nevrologi, professor PhD
  • Unn Ljøstad, spesialist i nevrologi, professor PhD
  • Åse Mygland, spesialist i nevrologi, professor dr med